

Rinat Yerushalmi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/584452/publications.pdf>

Version: 2024-02-01

71
papers

2,252
citations

567281

15
h-index

223800

46
g-index

74
all docs

74
docs citations

74
times ranked

3391
citing authors

#	ARTICLE	IF	CITATIONS
1	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	27.0	1,472
2	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	7.1	217
3	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. <i>Breast</i> , 2021, 60, 62-69.	2.2	88
4	Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. <i>Journal of Surgical Oncology</i> , 2006, 93, 529-533.	1.7	37
5	Pharmacological induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells. <i>Oncotarget</i> , 2014, 5, 11452-11463.	1.8	35
6	Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity. <i>Oncologist</i> , 2015, 20, 985-991.	3.7	33
7	Premature ovarian aging in <i>BRCA</i> carriers: a prototype of systemic precocious aging?. <i>Oncotarget</i> , 2018, 9, 15931-15941.	1.8	32
8	Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. <i>Oncology Letters</i> , 2015, 10, 2149-2155.	1.8	30
9	The association between smoking and breast cancer characteristics and outcome. <i>BMC Cancer</i> , 2017, 17, 624.	2.6	25
10	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
11	Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. <i>Breast</i> , 2021, 58, 173-181.	2.2	23
12	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3369-3379.	2.5	21
13	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	2.9	20
14	<i>BRCA1/2</i> mutations perturb telomere biology: characterization of structural and functional abnormalities <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 2433-2454.	1.8	19
15	Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion. <i>Clinical Breast Cancer</i> , 2018, 18, e267-e270.	2.4	18
16	A novel role for an old target: CD45 for breast cancer immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1929725.	4.6	12
17	Invasive Lobular Carcinoma of the Breast: Appearance on Digital Breast Tomosynthesis. <i>Breast Care</i> , 2016, 11, 359-362.	1.4	10
18	Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial. <i>Clinical Breast Cancer</i> , 2018, 18, e197-e203.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling. <i>Oncology</i> , 2019, 96, 14-24.	1.9	10
20	Perception of prognosis of cancer patients by non-oncologists. <i>International Journal of Clinical Practice</i> , 2016, 70, 1027-1032.	1.7	9
21	Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity"From Bench to Bedside. <i>Biomedicines</i> , 2020, 8, 577.	3.2	8
22	Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1070-1070.	1.6	8
23	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis. <i>PLoS ONE</i> , 2014, 9, e107273.	2.5	7
24	Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0138229.	2.5	7
25	The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 231-237.	2.5	7
26	GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment. <i>BMC Cancer</i> , 2020, 20, 333.	2.6	7
27	Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance imaging between BRCA gene mutation carriers and non-carriers. <i>Clinical Imaging</i> , 2018, 51, 347-351.	1.5	6
28	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. <i>Frontiers in Medicine</i> , 2021, 8, 675963.	2.6	6
29	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-9.	1.5	5
30	A Dedicated Follow-Up Clinic for BRCA Mutation Carriers. <i>Israel Medical Association Journal</i> , 2016, 18, 549-552.	0.1	5
31	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
32	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1069-1069.	1.6	4
33	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.9	4
34	Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?. <i>Breast Journal</i> , 2016, 22, 662-666.	1.0	3
35	Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	3
36	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Timing to imaging and surgery after neoadjuvant therapy for breast cancer. <i>Clinical Imaging</i> , 2021, 71, 24-28.	1.5	3
38	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 379-387.	2.5	3
39	Diagnostic workup of early-stage breast cancer: can we choose more wisely?. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 741-748.	2.5	2
40	Ethnicity, recurrence score distribution, and clinical outcomes in ER ⁺ HER2 ⁻ negative breast cancer patients in Israel: A registry analysis. <i>Breast Journal</i> , 2020, 26, 2096-2098.	1.0	2
41	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer. <i>Discover Oncology</i> , 2021, 12, 26.	2.1	2
42	COVID ⁻ 19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte colony ⁻ stimulating factor (G ⁻ CSF) support: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 117.	1.0	1
43	Genetic testing in patients with triple-negative or hereditary breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 584-590.	2.4	1
44	Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1071-1071.	1.6	1
45	Cardiotoxicity manifestations in metastatic breast cancer patients treated with trastuzumab as first line.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13011-e13011.	1.6	1
46	The association between treatment for metabolic disorders and breast cancer characteristics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 527-527.	1.6	1
47	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	2.5	0
48	Abstract PS1-50: Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. , 2021, , .		0
49	Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18791-e18791.	1.6	0
50	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. <i>Oncology</i> , 2021, 99, 713-721.	1.9	0
51	Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 202-202.	1.6	0
52	Chemotherapy-induced ovarian failure in young breast cancer patients: The role of vascular toxicity.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9595-9595.	1.6	0
53	Oncotype-DX recurrence score distribution among breast cancer patients harboring a germline mutation in the BRCA1/2 genes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 564-564.	1.6	0
54	The association between antihypertensive medications and breast cancer characteristics.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12000-e12000.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
56	Premature ovarian aging in <i>BRCA</i> carriers: Is it a prototype of systemic precocious aging?. Journal of Clinical Oncology, 2016, 34, e13016-e13016.	1.6	0
57	A prospective long term follow up of pulmonary diffusion capacity reduction caused by dose dense chemotherapy in breast cancer patients.. Journal of Clinical Oncology, 2018, 36, e12537-e12537.	1.6	0
58	Prognostic value of the detection of lympho-vascular invasion in hormone receptor positive early breast cancer in the era of molecular profiling.. Journal of Clinical Oncology, 2018, 36, e12539-e12539.	1.6	0
59	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 524-524.	1.6	0
60	Investigating the utility of breast cancer (BC) molecular signatures and immune signature profiling (ISP) as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy + trastuzumab (NAC+T) in HER2+ BC.. Journal of Clinical Oncology, 2019, 37, e12109-e12109.	1.6	0
61	Hormone replacement therapy (HRT) and risk of distant recurrence in newly diagnosed ER+, node-negative (N-) breast-cancer (BC) patients: A retrospective population-based matched-cohort study.. Journal of Clinical Oncology, 2019, 37, 6591-6591.	1.6	0
62	Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. Journal of Clinical Oncology, 2020, 38, e12587-e12587.	1.6	0
63	3,3'-Diindolylmethane (DIM): A nutritional intervention and its impact on breast density in healthy BRCA carriers compared to non-treated carriers" A prospective clinical trial.. Journal of Clinical Oncology, 2020, 38, 1556-1556.	1.6	0
64	The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, e12606-e12606.	1.6	0
65	The impact of endogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. Journal of Clinical Oncology, 2020, 38, e12605-e12605.	1.6	0
66	Abstract P2-11-16: Rate of breast biopsy referrals in <i>BRCA</i> mutation carriers: A retrospective comparative study and matched analysis. Cancer Research, 2022, 82, P2-11-16-P2-11-16.	0.9	0
67	Abstract P2-09-16: Clinicopathological features and outcome of breast cancer in CHEK2 germline mutation carriers. Cancer Research, 2022, 82, P2-09-16-P2-09-16.	0.9	0
68	Abstract P5-13-08: Identification of PD-L1+ status as a candidate predictive biomarker of response to talazoparib (TALA) in the phase 3 EMBRACA study. Cancer Research, 2022, 82, P5-13-08-P5-13-08.	0.9	0
69	Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry. Cancer Research, 2022, 82, P1-08-14-P1-08-14.	0.9	0
70	Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis. Breast Cancer Research and Treatment, 2022, , 1.	2.5	0
71	Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. Journal of Clinical Oncology, 2022, 40, 565-565.	1.6	0